Homma Y, Kawabe K, Kageyama S, Koiso K, Akaza H, Kakizoe T, Koshiba K, Yokoyama E, Aso Y
Department of Urology, Faculty of Medicine, University of Tokyo, Japan.
Int J Urol. 1996 Mar;3(2):124-7. doi: 10.1111/j.1442-2042.1996.tb00496.x.
Glutaraldehyde cross-linked (GAX) collagen has recently become available as injection material for treatment of urinary incontinence and should be evaluated for its long-term efficacy.
The subjects included 78 females with genuine stress incontinence (GSI) and 19 male or female patients with intrinsic sphincter deficiency (ISD: urinary incontinence due to urethral sphincter damage). GAX collagen was injected transperineally or transurethrally through an injection needle under direct endoscopic observation. The efficacy was evaluated by the patients' overall assessment at two years post-treatment.
Under local or regional anesthesia, GAX collagen was injected 1.9 times on average (total injection volume: 23.5 mL) in GSI patients and 2.2 times (40.1 mL) in ISD patients. Improvement at two years post-treatment by patients' assessment was observed in 71.7% of GSI patients and 53.3% in ISD patients. Side effects were urinary retention and difficulty in voiding after 48 of the total of 188 injections (25.5%), a large amount of residual urine in four (2.1%) and miscellaneous in 19 (10.1%), for a short period after injection and were not serious.
Our study indicates that GAX collagen injection is an effective, safe and easy non-medical treatment for urinary incontinent patients.
戊二醛交联（GAX）胶原蛋白最近作为治疗尿失禁的注射材料可供使用，应对其长期疗效进行评估。
研究对象包括78例真性压力性尿失禁（GSI）女性患者以及19例男性或女性内在括约肌缺陷（ISD：由于尿道括约肌损伤导致的尿失禁）患者。在直接内镜观察下，通过注射针经会阴或经尿道注射GAX胶原蛋白。通过患者治疗后两年的总体评估来评价疗效。
在局部或区域麻醉下，GSI患者平均注射GAX胶原蛋白1.9次（总注射量：23.5 mL），ISD患者平均注射2.2次（40.1 mL）。根据患者评估，治疗后两年GSI患者的改善率为71.7%，ISD患者为53.3%。在总共188次注射中有48次（25.5%）出现的副作用为注射后短期内尿潴留和排尿困难，4例（2.1%）出现大量残余尿，19例（10.1%）出现其他杂项副作用，且均不严重。
我们的研究表明，GAX胶原蛋白注射对于尿失禁患者是一种有效、安全且简便的非药物治疗方法。
